Latest Period
Q1 2026
Security Snapshot
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) Institutional Ownership
CUSIP: 482929106
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
57
Shares (Excl. Options)
18,578,668
Price
$5.77
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KLRS on Nasdaq
- Shares outstanding
- 23,801,814
- Price per share
- $6.59
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 18,578,668
- Total reported value
- $107,183,840
- % of total 13F portfolios
- 0%
- Share change
- +592,237
- Value change
- +$2,953,838
- Number of holders
- 57
- Price from insider filings
- $6.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 482929106.
- 57 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 51 to 57 between Q4 2025 and Q1 2026.
- Reported value moved from $151,883,912 to $107,183,840.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 57 institutions filings for Q1 2026.
Security key
482929106
Latest holder period
Q1 2026
13F holders
57
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
KLRS full holder history
Kalaris Therapeutics, Inc. SEC filings
Kalaris Therapeutics, Inc. company facts
Kalaris Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482929106:
Significant Owners of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 54% | -4% | $85,014,842 | -$349,257 | 12,900,583 | -0.41% | Srinivas Akkaraju | 20 May 2026 |
| RTW INVESTMENTS, LP | 5.7% | $12,714,000 | 1,300,000 | RTW Investments, LP | 31 Dec 2025 | |||
| GILEAD SCIENCES, INC. | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | |||
| Invus Global Management, LLC | 1.5% | $754,533 | 282,586 | Invus Public Equities, L.P. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 1.1% | $1,315,201 | 201,718 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 31 Mar 2026, 57 institutional investors reported holding 18,578,668 shares of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS). This represents 78% of the company’s total 23,801,814 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 54% | 12,948,081 | 0% | 7.3% | $74,710,427 |
| RTW INVESTMENTS, LP | 5.5% | 1,300,000 | 0% | 0.07% | $7,501,000 |
| Paradigm Biocapital Advisors LP | 2.9% | 700,000 | 0% | 0.08% | $4,039,000 |
| Alyeska Investment Group, L.P. | 2.4% | 572,687 | +42% | 0.01% | $3,274,750 |
| Siren, L.L.C. | 1.8% | 435,798 | 0% | 0.07% | $2,514,554 |
| Ikarian Capital, LLC | 1.5% | 360,000 | 0% | 0.3% | $2,077,200 |
| Propel Bio Management, LLC | 1.2% | 295,771 | +603% | 1.1% | $1,721,024 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1% | 255,348 | 0% | 0% | $1,473,358 |
| Kalehua Capital Management LLC | 0.57% | 135,585 | -3.1% | 0.55% | $782,325 |
| RAYMOND JAMES FINANCIAL INC | 0.5% | 118,887 | +34% | 0% | $685,978 |
| GOLDMAN SACHS GROUP INC | 0.46% | 110,503 | +222% | 0% | $637,602 |
| ADAR1 Capital Management, LLC | 0.42% | 100,000 | 0% | 0.03% | $577,000 |
| Woodline Partners LP | 0.42% | 100,000 | 0% | 0% | $577,000 |
| WHI TRUST Co LLC | 0.41% | 97,493 | 0% | 0.42% | $562,535 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.39% | 92,261 | 0% | 0.01% | $532,346 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.37% | 87,545 | +5.9% | 0% | $505,341 |
| Simplify Asset Management Inc. | 0.37% | 87,426 | +336% | 0.01% | $504,448 |
| MARSHALL WACE, LLP | 0.29% | 67,879 | -6.9% | 0% | $391,662 |
| RENAISSANCE TECHNOLOGIES LLC | 0.28% | 66,151 | -25% | 0% | $381,691 |
| MILLENNIUM MANAGEMENT LLC | 0.25% | 59,534 | 0% | $343,511 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.22% | 52,684 | +310% | 0% | $303,987 |
| 683 Capital Management, LLC | 0.19% | 45,000 | -44% | 0.02% | $259,650 |
| Belpointe Asset Management LLC | 0.17% | 40,000 | 0% | 0.01% | $230,800 |
| Fortis Capital Advisors, LLC | 0.17% | 40,000 | 0% | 0.03% | $230,800 |
| Squarepoint Ops LLC | 0.17% | 39,773 | +57% | 0% | $229,490 |
Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 18,578,668 | $107,183,840 | +$2,953,838 | $5.77 | 57 |
| 2025 Q4 | 17,996,162 | $151,883,912 | +$39,427,360 | $8.44 | 51 |
| 2025 Q3 | 13,222,873 | $76,428,251 | +$1,455,559 | $5.78 | 31 |
| 2025 Q2 | 13,362,268 | $35,677,274 | -$2,639,077 | $2.67 | 29 |
| 2025 Q1 | 13,874,350 | $111,411,096 | +$111,410,076 | $8.03 | 31 |